MetLife's Board Approved a New $3 Billion Buyback on August 5, 2026 — on Top of $400 Million Still Unspent From the Last One

MetLife's board of directors approved a new $3.0 billion authorization to repurchase the company's common stock, the insurer announced on August 5, 2026. The new capacity is layered on top of roughly $400 million remaining under a previous buyback program authorized in April 2025 — MetLife is adding fresh authorization well before exhausting the prior one, rather than replacing a program that had run dry.

CEO Michel Khalaf described the move as reflecting confidence in MetLife's long-term outlook and its continued ability to generate capital. For a large life and annuity insurer, that capital-generation capacity is a function of underwriting results, investment income, and regulatory capital requirements specific to the insurance business — a buyback of this scale is effectively management signaling that statutory and GAAP capital generation is running ahead of what the business needs to reinvest or hold in reserve.

As with any repurchase authorization, the $3.0 billion figure is a ceiling on what MetLife may spend, not a commitment to spend it on any particular timeline. Actual repurchases will depend on the share price, prevailing market conditions, and the company's capital needs, and the program carries no fixed expiration date — the company retains full discretion over pace and total amount.

MET's stock reaction to the announcement was muted. A $3 billion authorization is a large absolute number, but it is broadly consistent with the scale of capital return large-cap insurers with MetLife's balance sheet routinely announce, which likely limited any surprise-driven price move — the market treats routine, well-telegraphed capital-return increases differently from a buyback tied to a specific unexpected catalyst.